by Ulcerative colitis is an inflammatory bowel disease that causes long-lasting inflammation and ulcers in the colon and rectum. The disease arises due to an abnormal response by the immune system in the intestinal tract leading to symptoms such as abdominal pain, rectal bleeding, bloody diarrhea and the urge to empty the bowels frequently. The United Kingdom ulcerative colitis market is a significant area of focus for major pharmaceutical companies given the increasing disease prevalence in the country.
The UK ulcerative colitis market is primarily driven by the growing adoption of biologic drugs for disease management. Biologics offer targeted mechanisms that inhibit specific inflammatory pathways making them highly effective for managing moderate to severe cases of ulcerative colitis. The biologics segment within the UK market accounted for over 30% share in 2021 led by top brands such as infliximab and adalimumab.
The Global United Kingdom Ulcerative Colitis Market Size is estimated to be valued at US$ 421.3 Mn in 2024 and is expected to exhibit a CAGR of 3.4% over the forecast period of 2024-2031.
Key Takeaways
Key players operating in the UK ulcerative colitis market are AbbVie Inc. (Allergan, Inc.), Merck & Co., Inc., Novartis AG, Bausch Health Companies Inc., and Johnson & Johnson.
There is growing demand for ulcerative colitis treatment options in the UK due to rising disease prevalence. As per epidemiological studies, it is estimated that there are over 146,000 prevalent cases of ulcerative colitis in the country representing over 200 new cases diagnosed annually.
Major pharmaceutical companies are focusing on expanding their geographic footprint in the UK to tap into the market potential. Several biologics manufacturers have either received marketing authorization or have drugs in the late stages of clinical trials to strengthen their product portfolio for the UK UC market.
Market Key Trends
The increased adoption of biosimilars is a major trend being witnessed in the UK ulcerative colitis market. The development of biosimilar versions of infliximab and adalimumab has created pricing competition and given patients more affordable treatment options. This has allowed an increasing number of patients in the UK access to biologic therapy for ulcerative colitis management. Personalized treatment approaches utilizing biomarkers to predict disease progression and treatment responses also holds promise for improving overall disease management in the coming years.
Porter’s Analysis
Threat Of New Entrants: High capital requirements in terms of infrastructure, manufacturing, distribution network etc. makes the threat of new entrants low in this market.
Bargaining Power Of Buyers: Large number of buyers and prevalence of generic medications provides moderately high bargaining power to the buyers in this market.
Bargaining Power Of Suppliers: Large number of raw material suppliers and manufacturers with sufficient capacity gives moderately low bargaining power to suppliers in this market.
Threat Of New Substitutes: Limited threat from new substitutes due to lack of revolutionary new treatment options.
Competitive Rivalry: High due to presence of many international and local players offering similar therapies.
Geographical Regions
North America region accounts for the largest share of the United Kingdom ulcerative colitis market in terms of value due to high per capita healthcare expenditure and growing demand for biologics and biosimilars in the region.
Asia Pacific region is expected to witness the fastest growth over the forecast period owing to growing prevalence of ulcerative colitis, improving healthcare infrastructure and increasing healthcare spending in major Asian countries like China and India.
What Are The Key Data Covered In This United Kingdom Ulcerative Colitis Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the United Kingdom Ulcerative Colitis’s growth between 2024 and 2031.
:- Accurate calculation of the size of the United Kingdom Ulcerative Colitis and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- United Kingdom Ulcerative Colitis Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of United Kingdom Ulcerative Colitis vendors
FAQ’s
Q.1 What are the main factors influencing the United Kingdom Ulcerative Colitis?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top United Kingdom Ulcerative Colitis companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the United Kingdom Ulcerative Colitis’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
